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Abstract Activities of the retinoic acid receptor (RAR)a
and RARc are important to hematopoiesis. Here, we have
investigated the effects of receptor selective agonists and
antagonists on the primitive human hematopoietic cell lines
KG1 and NB-4 and purified normal human hematopoietic
stem cells (HSCs). Agonizing RARa (by AGN195183) was
effective in driving neutrophil differentiation of NB-4 cells
and this agonist synergized with a low amount (10 nM) of
1a,25-dihydroxyvitamin D3 to drive monocyte differenti-
ation of NB-4 and KG1 cells. Treatment of cultures of
human HSCs (supplemented with stem cell factor ± in-
terleukin 3) with an antagonist of all RARs (AGN194310)
or of RARa (AGN196996) prolonged the lifespan of cul-
tures, up to 55 days, and increased the production of
neutrophils and monocytes. Slowing down of cell differ-
entiation was not observed, and instead, hematopoietic
stem and progenitor cells had expanded in number.
Antagonism of RARc (by AGN205728) did not affect
cultures of HSCs. Studies of CV-1 and LNCaP cells
transfected with RAR expression vectors and a reporter
vector revealed that RARc and RARb are activated by sub-
nM all-trans retinoic acid (EC50–0.3 nM): *50-fold more
is required for activation of RARa (EC50–16 nM). These
findings further support the notion that the balance of
expression and activity of RARa and RARc are important
to hematopoietic stem and progenitor cell expansion and
differentiation.
Keywords Retinoic acid receptor  Hematopoiesis 
Neutrophils  Monocytes  All-trans retinoic acid 
Agonist  Antagonist
Introduction
Retinoic acid receptors (RARs) are members of the nuclear
hormone receptor superfamily, and there are three main
isoforms of RAR in vertebrates: RARa, b, and c (Chambon
1996; Sucov and Evans 1995). RARs form heterodimers
with retinoid X receptors which bind to retinoic acid
response elements (RAREs) in the promoter/enhancer
regions of target genes to either activate or repress gene
transcription (Kastner et al. 1997). Activation versus
repression of transcription by RARs is affected by binding
or otherwise of the natural ligand all-trans retinoic acid
(ATRA) which influences the recruitment of either core-
pressors or coactivators of transcription (Niederreither and
Dolle´ 2008). In the absence of ATRA, RARa binds the
silencing mediator of retinoic acid and thyroid hormone
receptor/nuclear receptor corepressor family of corepres-
sors resulting in the formation of a histone deacetylase
repressor complex at RAREs and repression of transcrip-
tion. Binding of ATRA to RARa leads to the release of
corepressors, recruitment of coactivators, and gene tran-
scription. In contrast to RARa, b and c have been reported
to activate gene transcription without having bound ligand,
and in this case, binding of ATRA serves to increase
activation (Farboud et al. 2003; Hauksdottir et al. 2003).
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RARs are important regulators of vertebrate develop-
ment as to cells making fate decisions and then undergoing
differentiation (reviewed in Mendoza-Parra and Grone-
meyer 2013). Expression of the different isoforms varies
temporally during development and, in regard to cell type,
pointing to the isoforms having different functions rather
than functional redundancy (Dolle´ et al. 1990; Germain
et al. 2006; Kastner et al. 1995). Findings from RAR-
knockout mice emphasize the importance of RARs to
development. Ocular defects and reduced body weight are
seen in RARb-knockout mice, RARb-knockout mice have
severe defects, and knockout of two or more receptors is
generally lethal (Ghyselinck et al. 1997; Li et al. 1993;
Lohnes et al. 1993; Subbarayan et al. 1997). There are not
obvious defects in the RARa-knockout mouse, and in
humans, abnormality in regard to expression/function of
this isoform is associated with malignancy. In acute
promyelocytic leukemia (APL), chromosome transloca-
tions lead to chimeric RARa proteins that result in a block
in myeloid cell differentiation at the promyelocyte stage
(reviewed in Ablain and de The´ 2014). As to other isoforms
and malignancy, RARc is reported to be an oncogene in
hepatocellular carcinoma (Yan et al. 2010).
RARa and RARc are important regulators of the dif-
ferentiation of hematopoietic cells. Agonizing RARa,
using ATRA or a selective agonist, promotes the differ-
entiation of normal myeloid progenitor cells (Gratas et al.
1993) and promyeloid cell lines, such as HL60 cells, which
respond by differentiating towards neutrophils (Breitman
et al. 1980). ATRA may also be involved in specifying a
granulocyte fate, as this agent appears to orient pluripotent
hematopoietic progenitors towards the granulocyte lineage
(Tocci et al. 1996). In keeping with these roles for RARa,
the RAR fusion proteins that arrest myeloid differentiation
of APL cells function as dominant-negative inhibitors of
wild-type RARa (reviewed in Tsai and Collins 1993; Yan
et al. 2010). A shift provoked by the fusion proteins to
attract a novel repertoire of corepressors has been proposed
to contribute to this action (Mengeling et al. 2011). Though
ATRA clearly promotes neutrophil differentiation, the
influence of RARa is modulatory: RARa is dispensable as
evidenced by RARa-/- mice which make neutrophils.
Kastner concluded that RARa modulates granulopoiesis in
a bi-directional manner, with ligand-bound receptor pro-
moting differentiation and ligand-free receptor inhibiting it
(Kastner et al. 2001).
Agonizing RARc appears to oppose the ligand-driven
action of RARa by interfering with the capacity of
hematopoietic stem cells (HSCs) to undergo differentiation
and promoting self-renewal and/or proliferation. A reduced
number of HSCs in the c-knockout mouse highlight the
importance of RARc to hematopoiesis, and loss of RARc
also abrogated the capacity of ATRA to potentiate the
maintenance of HSC in culture. Purton et al. (2006) con-
cluded that RARc plays a critical role in regulating whether
HSC self-renew and maintain their pluripotency versus
embark on differentiation. Like RARa, the role of RARc is
modulatory, as HSCs are still present in the knockout
mouse. That RARc has a role in allowing cells to maintain
pluripotency, is further supported by the finding that
addition of RARc to the Yamanaka cocktail of transcrip-
tion factors used to generate induced pluripotent stem cells
from somatic cells improves the efficiency, by which these
cells can be generated (Wang et al. 2011).
Here, we utilized agonists and antagonists of RARs that
are highly selective for RAR receptor isoforms to examine
further the influence of RARa and RARc on the growth
and differentiation of promyeloid cell lines and normal
human HSCs. In regard to the reported constitutive activity
of RARc, we examine whether transactivation of RARa




1a,25-Dihydroxyvitamin D3 (1,25D) was obtained from
Cayman Europe (Tallinn, Estonia), while ATRA and
TTNPB were from Sigma (St Louis, MO, USA). The
compounds were dissolved in absolute ethanol at a con-
centration of 10 lM and stored at -20 C. The synthetic
retinoids AGN195183, AGN194310, AGN196996, and
AGN205728 were synthesized at the Shanghai Institute of
Materia Medica. Their synthesis, development, and speci-
ficities have been described previously (Hughes et al. 2006;
Johnson et al. 1995; Klein et al. 1996; Nagpal et al. 1995;
Nagpal and Chandraratna 1996, 2000; Teng et al. 1996).
Retinoids were dissolved in 50 % methanol/50 %
dimethylsulphoxide (DMSO) at a concentration of 10 mM
(stored at -20 C), and this stock was diluted using culture
medium to the required concentration. Rabbit polyclonal
antibodies to RARa (sc-550), RARb (sc-552), and to actin
(sc-1616), and a mouse monoclonal antibody to HDAC1
(sc-7872) were from Santa Cruz Biotechnology Inc.
Cell Lines
NB-4 and KG1 cells were obtained from the German
Resource Center for Biological Material (DSMZ GmbH,
Braunschweig, Germany). The cells were grown in RPMI-
1640 medium supplemented with 10 % fetal bovine serum
(FBS), 100 U/ml penicillin, and 100 lg/ml streptomycin
(Sigma, St Louis, MO, USA). Cells were grown at 37 C in
5 % CO2. Cell differentiation of NB-4 and KG1 cells was
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induced by incubating with 10 nM 1,25D ± 1 lM ATRA
or 100 nM retinoids for 96 h.
Primary Cultures of Human CD341ve Cells
The cells used were CD34?ve cells purified from the blood
of normal human adult donors and post-mobilization of
stem cells to the blood. Cells obtained and purified in this
manner are used routinely by the National Blood Service
Stem Cell Laboratory in Birmingham for bone marrow
transplantation. Ethics approval for the use of adult human
blood-mobilized stem cells (CD34?vehuHSC) was from the
West Midlands Research Ethics Committee. Informed
consent was obtained by the regional National Blood Ser-
vice Stem Cell Laboratory in Birmingham. CD34?ve cells
were purified to 99 % CD34?ve, 97 % CD133?ve,[99 %
lineage-ve (n = 15) using an anti-CD34 monoclonal anti-
body, immunomagnetic beads, and a CliniMACS magnetic
separator. Purified cells were plated at 5 9 105 cells/ml in
microtiter wells in 200 ll of either RPMI-1640 medium (R
and D Systems, Abingdon, UK) or HPGMTM hematopoi-
etic growth medium (Lonza, UK) containing either 10 %
FBS or 10 % human serum, antibiotics (100 U/ml peni-
cillin and 100 lg/ml streptomycin) and stem cell factor
(SCF), interleukin (IL)-3, and granulocyte-colony stimu-
lating factor (G-CSF) (all from R and D Systems
Abingdon, UK) as stated in the results. Cultures were fed
every 2–3 days (with fresh compound), split into microtiter
wells, and then expanded into 2 ml Costar wells to main-
tain a cell density of between 2.5 and 10 9 105 cells/ml.
Cells were grown at 37 C in 5 % CO2. Viable cells were
enumerated by phase contrast microscopy (4009
magnification).
Assays for Progenitor Cells
Assays for week-five cobblestone area forming cells
(CAFC), long-term culture-initiating cells (LTC-IC), and
colony-forming units (CFU) were performed at the Stem
Cell Laboratory at the National Blood Service Stem Cell
Laboratory using standard procedures and methods, as
described by other workers (de Wynter and Ploemacher
2001; Denning-Kendall et al. 1996; Nicol et al. 1996). CFU
assays were performed using MethocultTM GF H8444
(StemCell Technologies) and in 35 mm petri dishes. The
presence of CAFC was scored as the presence of 12 or more
closely associated and small cells that were embedded in the
MS5 cell feeder layer and blind by an experienced reader.
The nature of CFUs, as to colony-forming unit-granulocyte/
erythroid/megakaryocyte/monocyte (CFU-GEMM), col-
ony-forming unit-granulocyte/macrophage (CFU-GM),
burst-forming unit-erythroid (BFU-E), and colony-forming
unit-erythroid (CFU-E), was scored blind at the service by a
person who routinely reads colony assays and is accredited.
The nature of colonies was confirmed by sampling colonies
and staining cytocentrifuged preparations of cells.
Assessment of Cell Differentiation
The expression of differentiation markers at the cell surface
was determined by flow cytometry. Differentiation of NB-4
and KG1 cells was measured by staining using the mono-
clonal antibodies CD11b-FITC and CD14-PE and
appropriately labeled isotype controls (all from Immuno-
Tools, Friesoythe, Germany). Differentiation of human
CD34?ve cells was measured by triple-color staining using
various cocktails of phycoerythrin-, fluorescein isothy-
ocyanate-, and PerCP-monoclonal antibodies (from
Becton–Dickinson, San Jose, CA, USA). The markers used
to identify cell populations were as follows: CD45?ve
leukocytes; CD34?ve/CD133?ve HSCs; CD33?ve/CD13?ve
immature myeloid; CD117?ve myeloblasts and promyelo-
cytes; CD11b?ve/CD15?ve mature myeloid; CD11b?ve/
CD65?ve neutrophils; CD11b?ve/CD14?ve monocytes;
glycophorin?ve A erythroid cells; CD61?ve megakary-
oblasts and platelets; CD2?ve/CD5?ve/CD7?ve T cells and
NK cells; CD56?ve NK cells; CD19?ve/CD20?ve B cells;
and CD10?ve B lymphocyte progenitors; and present on
mature neutrophils and DR?ve progenitors and present on
mature monocytes. The cells were stained with 1 ll of the
fluorescently labeled antibody (or the appropriate control
immunoglobulin) for 1 h on ice. Next, they were washed
with ice-cold phosphate-buffered saline (PBS) and sus-
pended in 0.5 ml PBS supplemented with 0.1 % bovine
serum albumin (Sigma, St Louis, MO, USA) prior to
analysis on FACS Calibur flow cytometer (Becton–Dick-
inson, San Jose, CA, USA). The acquisition parameters
were set for an isotype control. Cells were analyzed using a
FACSCalibur, and data analysis was performed using the
CellQuest Pro software (Becton–Dickinson, San Jose, CA,
USA).
Measurement of mRNA and Protein Levels
for RARs
Isolation of total RNA, reverse transcription into cDNA,
and real-time PCR reactions were performed as described
previously (Gocek et al. 2012), using the CFX Real-time
PCR System (Bio-Rad Laboratories Inc., CA, USA). The
RARA, RARB, and RARG primers were obtained from
RealTimePrimers.com (Real Time Primers, LLC, PA,
USA), and GAPDH primers were as published (Baurska
et al. 2011). Quantification of gene expression was ana-
lyzed with the DDCq method using GAPDH as the
endogenous control. Primer efficiencies were measured in
all cell lines using a real-time PCR reaction based on the
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slope of the standard curve. The results were normalized to
primer efficiencies to compare gene expression in different
cell lines. Real-time PCR assays were performed at least in
triplicate.
Western Blotting
The cytosolic and nuclear lysates were obtained using NE-
PER Nuclear and Cytoplasmic Extraction Reagent
(Thermo Fisher Scientific Inc., Worcester, MA, USA)
according to the user’s manual. 6 9 106 cells per sample
were washed with PBS and lysed in 200 ll of cytoplasmic
extraction buffer, and centrifuged, and the remaining pel-
lets were lysed in 100 ll of nuclear extraction buffer. The
buffers contained a cocktail of protease inhibitors (Bio-
Tools, Inc., Jupiter, FL, USA). The lysates obtained were
denatured by adding five times sample buffer and boiling
for 5 min. For Western blotting, 25 ll of each lysate were
separated on 10 % SDS-PAGE gels and transferred to
PVDF membranes. The membranes were then dried, and
incubated sequentially with primary antibody (3 h) and a
horseradish peroxidase-conjugated secondary antibody
(1 h) at room temperature. The protein bands were visu-
alized by chemiluminescence (Santa Cruz).
Retinoid Receptor Transactivation Assays
For transactivation studies, we used CV-1 kidney fibroblast
cells and LNCaP prostate adenocarcinoma cells that can be
readily and reproducibly transfected with plasmids and
reporters. Transactivation assays using CV-1 cells were
undertaken essentially as described previously (Nagpal
et al. 1995). Briefly, CV-1 cells were transiently transfected
with a plasmid-containing ERE-tk-Luc promoter-reporter
construct using Lipofectamine as described in the manu-
facturer’s protocol (Fisher Scientific, Loughborough, UK).
ERE-tk-Luc transcript comprises a luciferase reporter
under control of an estrogen receptor response element.
The cells were also transiently transfected with expression
vector encoding a fusion protein containing the ligand-
binding domain of RARa, RARb, or RARc fused to an
estrogen receptor DNA-binding domain. Twenty-four
hours after transfection, the cells were treated with reti-
noids under test for 16 h in culture medium-containing
2.5 % charcoal-treated FBS and lysed for determination of
luciferase and b-galactosidase activities. Luciferase activ-
ity was measured using the Dual-Luciferase Reporter 100
Assay System (Promega, Southampton, UK), and b-
galactosidase activity was determined by colorimetric
assay. The reporter activity was normalized against b-
galactosidase activity. The transactivation data are pre-
sented as the percentage ± SEM of the maximal response
produced by 1 lM ATRA. The prostate adenocarcinoma
cell line LNCaP was transiently transfected with a pSG5-
RARa1 or pSG5-RARc1 mammalian expression vector
together with a pT109-DRG5-luc luciferase reporter under
the control of a DR5G RARE (constructed by Dr. Kevin
Petrie and Arthur Zelent, Institute of Cancer Research,
Sutton, UK). Cells were transfected using Lipofectamine
according to the manufacturer’s instructions and treated
and assayed as above.
Statistical Analyses
All assays were performed in triplicate. Results were sta-
tistically analyzed by a one-way ANOVA and Student’s
t test to determine the significance of differences in values
obtained from control and treated groups using the Sig-
mastatTM software package (Systat Software Inc. London).
Difference in statistical significance was set at p B 0.05.
Concentration response curves were fitted to the Hill
equation and ED50s estimated using the SigmaPlot
TM
software package (version 10 containing the ‘‘pharmacol-
ogy’’ module, Systat Software Inc. London).
Results
Pharmacological Properties of the Synthetic RAR
Isoform-Specific Retinoids
The RAR-selective compounds are highly specific agonists
and antagonists as reported elsewhere (Hammond et al.
2002; Hughes et al. 2006; Nagpal et al. 1995). The agonists
stimulate transactivation in CV-1 cells transfected with an
appropriate RAR expression vector and reporter construct.
The antagonists failed to do so for RAR transfected CV-1
cells, and instead, blocked ATRA- and TTNPB-stimulated
RAR transactivation in a dose responsive fashion. The
binding affinities of compounds at individual isoforms of
RAR and RXR are shown in Table 1. The receptor selec-
tive a agonist AGN195183 binds with a high affinity to
RARa (ED50 20.1 nM). The pan-antagonist AGN194310
and receptor selective a antagonist AGN196996 and c
antagonist AGN205728 bind with high affinities to all
RARs (ED50 4.3, 5, and 2 nM), RARa (ED50 3.9 nM), and
RARc (ED50 3 nM), respectively.
Agonizing RARa Drives Differentiation of NB-4
and KG1 Cells
The human promyeloid cell line HL60 differentiates
towards neutrophils in response to ATRA (Breitman et al.
1980). Previously, we used agonists and antagonists of
RAR isoforms and retinoid X receptor and a HL60 sub-line
that expresses a dominant-negative RARa to show that
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ATRA-provoked differentiation of HL60 cells requires
activation of RARa which forms heterodimers with reti-
noid X receptor (Hughes et al. 2006).
The NB-4 cell line harbors one copy of the wild-type
RARA gene and one copy of the PML-RARA fusion gene,
which encodes the fusion protein PML-RARa (Lanotte
et al. 1991). KG1 cells express the fusion gene
FGFR1OP2-FGFR1 encoding the fusion protein FOP2-
FGFR1 which activates the STAT signaling pathways (Gu
et al. 2006). The expression levels of RARA, RARB, and
RARG genes in these cells were measured, relative to
GAPDH expression levels, using Real-time PCR.
Figure 1a shows that both cell lines express high levels of
RARB, moderate levels of RARA, while RARG mRNA is
almost undetectable. The presence of respective proteins
in cytoplasmic and nuclear fractions of lysates, prepared
from equal numbers of NB-4 and KG1 cells, was inves-
tigated by Western blotting (Fig. 1b). Comparison of
Fig. 1a and b reveals that the levels of protein and
mRNAs do not match. The RARa isoform was readily
detected in lysates and the antibodies against RARb and
RARc did not give a detectable signal. RARa was
detected only in lysates of the nuclei of both cell lines
with KG1 cells expressing RARa at a higher level than
NB-4 cells, when normalized to the level of histone
deacetylase 1 (HDAC1), which also confirmed the purity
of nuclear lysates.
Figure 1c shows that NB-4 cells differentiated towards
monocytes (CD11b?ve/CD14?ve) to a small extent when
treated with a high dose (1 lM) of ATRA (*10 %
CD11b?ve/CD14?ve cells) and a low dose (10 nM) of
1,25D (*6 % CD11b?ve/CD14?ve cells). The combined
use of 10 nM 1,25D and 1 lM ATRA increased the level
of monocyte differentiation to *36 %. Figure 1c shows
that 100 nM of the a agonist AGN195183 effectively
induced neutrophil differentiation of NB-4 cells to a level
of 40 % CD11b?ve/CD14-ve cells. AGN195183 was also
more effective than ATRA when used in combination with
10 nM 1,25D to induce monocyte differentiation. 100 nM
of AGN195183 was sufficient, as compared with 1 lM
ATRA, to give rise to 40 % CD11b?ve/CD14?ve cells. Pan,
a, and c antagonists had no effect on NB-4 cells when used
alone, and the antagonists did not have an appreciable
effect when used with 10 nM 1,25D as compared with the
use of 1,25D alone.
Figure 1d shows that treatment of KG1 cells with
ATRA and the a agonist AGN195183 led to a low level of
neutrophil differentiation of between 5 and 10 %
CD11b?ve/CD14-ve cells. Both ATRA and AGN195183
when used in combination with 10 nM 1,25D resulted in a
significant level of differentiation towards monocytes.
Percentages of CD11b?ve/CD14?ve cells were 26 and
18 %, respectively. Again, the a agonist was observed to
be more potent than ATRA, as this agent was used at
100 nM compared to 1 lM ATRA. The pan, a, and c
antagonists had no effect on KG1 cells when used alone
and together with 1,25D. Representative histograms which
show the levels of differentiation induced by the a agonist,
1,25D or both agents are presented in Fig. 1e for NB-4
cells and in Fig. 1f for KG1 cells.
Antagonism of RARs Increases the Production
of Myeloid Cells by CD341vehuHSC-Initiated
Cultures
The phenotype of the CD34 column purified cells as to
surface markers associated with hematopoietic stem and
progenitor cells was 95.3 ± 1.7 CD133?ve, 98.1 ± 0.6
CD34?ve, 84.7 ± 4.7 CD117?ve, 90.1 ± 3.0 CD38?ve, and
91.1 ± 3.0 HLA-DR?ve (n = 15 donors). The levels of
contamination by myeloid- (CD14, CD15, CD11b and
CD64), erythroid- (glycophorin A), T-cell- (CD3, CD5,
CD7, CD8 and CD27), and B-cell lineage- (CD19) asso-
ciated cells were 0.9 ± 0.1, 0.8 ± 0.1, 1.0 ± 0.1, and
1.6 ± 0.5, respectively.
CD34?vehuHSC spontaneously and progressively
mature giving rise largely to mature myeloid cells when
cultured in a various growth media, sources of serum, and
often SCF and IL-3. As such, CD34?veHSC cannot be
reliably expanded in culture. To obtain differentiating
myeloid cells from CD34?vehuHSC in numbers sufficient
for biochemical studies, we have routinely cultured these
cells in a low amount of human recombinant IL-3 ± G-
CSF (Mountford et al. 1994). From past studies 10 % FBS,
100 ng/ml SCF, 5 ng/ml IL-3, and 30 ng/ml G-CSF give
the best yield of mature myeloid cells from CD34?ve-
huHSC. We used these conditions as a benchmark to the
optimal generation of myeloid cells.
Table 1 Binding affinities (ED50 in nM) of synthetic retinoids
against different RAR isoforms
Retinoids RARa RARb RARc Classification
RAR agonists
AGN195183 20.1 [5000 [5000 RARa
RAR antagonists
AGN194310 4.3 5 2 RARabc
AGN196996 3.9 4036 [10,000 RARa
AGN205728 2400 4248 3 RARc
Nuclear extracts were prepared from baculovirus-infected Sf21 insect
cells engineered to express either human RARa, b, or c, or RXRa, b,
or c as described (Allegretto et al. 1993; Nagpal et al. 1995). The
equilibrium-binding affinities of each retinoid analog (ED50 in nM)
were estimated by the abilities of non-labelled synthetic retinoids to
compete with the binding of [3H]-ATRA to a RAR isotype as
described (Heyman et al. 1992). Affinities against RXRs
were[10,000 nM
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Fig. 1 Agonism of RARa is sufficient to drive differentiation of NB-
4 and KG1 cells. The expression of RAR isoforms was measured in
NB-4 and KG1 cells as to mRNA (a) and protein (b) levels. The
expressions RARA, RARB, and RARG were examined in NB-4 and
KG1 cells by Real-time PCR and relative to GAPDH expression
levels. The expression level obtained for RARA in NB-4 cells was
calculated as 1. The bar charts show mean values (±SD) of the
relative quantity (RQ). The levels of RARa protein were determined
in NB-4 and KG1 cells by Western blots. The cytosolic (C) and
nuclear (N) extracts were separated by SDS-PAGE, transferred to
PVDF membranes, and the proteins were revealed using anti-RARa,
anti-actin, and anti-HDAC1 antibodies. NB-4 (c) and KG1 (d) cells
were exposed to 1 lM ATRA or to 100 nM synthetic retinoids with
or without 10 nM 1,25D for 96 h. The synthetic retinoids were the a
agonist AGN195183, pan-antagonist AGN194310, a antagonist
AGN196996, and the c antagonist AGN205728. Cell surface
expression of the CD11b and CD14 differentiation markers was
detected by flow cytometry to enumerate cells that had differentiated
towards neutrophils (CD11b?veCD14-ve) and monocytes (CD11b?-
veCD14?ve). The bar charts show the mean ± SEM of the values
obtained from triplicate cultures. *Values that are significantly higher
than control sample; #values that are significantly higher than ATRA-
treated sample and &values that are significantly higher than 1,25D-
treated sample. Representative histograms are presented for NB-4
(e) and KG1 (f) cells. The grey area represents the expression of a
given cell surface marker in untreated cells, the black line in a
agonist-treated cells, the blue line in 1,25D-treated cells, and the red
line in cells treated with combination of both agents
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Control cultures (FBS, SCF, and IL-3) of CD34?veHSC
and cultures supplemented with either the pan-RAR
antagonist AGN194310 or G-CSF progressively differen-
tiated giving rise mostly to neutrophils and monocytes.
During the lifespan of the cultures, the percentage of ery-
throid cells (glycophorin A) varied between 5 and 8 %,
megakaryocyte lineage cells (CD61) were between 7 and
9 %, and B lymphocytes (CD19/CD20) and T lympho-
cytes/NK cells (CD2/CD3/CD7/CD56) were\1 %. In
control cultures, cell production peaked at day 20 with
around 1 9 107 cells generated, and mature neutrophils
and monocytes were present in almost equal proportions
(Fig. 2b). After day 20, cell production declined rapidly
and the cultures had started to expire (cell den-
sity\0.5 9 105/ml) by day 30. The addition of 10 nM of
the pan-antagonist AGN194310 led to a substantial and
sustained increase in cell production, as revealed by the
cumulative cell number. By day 20, around fourfold more
cells had been produced in the antagonist-treated cultures
than in control cultures, and the antagonist-treated cultures
were maintained for as long as 55 days. An almost iden-
tical kinetic was observed for cultures supplemented with
100 nM AGN194310 (data not shown). Increased cell
production by the antagonist-treated cultures up to day 20
was not attributable to a higher level of dead/apoptotic
cells in control cultures, as few dead/apoptotic cells were
present in both culture conditions, as observed by phase
contact microscopy when counting cells and cells gated out
in FACS analyses. As seen for control cultures, similar
numbers of mature neutrophils and monocytes were pro-
duced in the antagonist-treated cultures (Fig. 2). The
kinetic of increased production of total and myeloid cells
Fig. 2 Antagonism of RARs increases neutrophil production in
cultures of human haematopoietic stem cells. Purified human
haematopoietic stem cells (CD133?ve/CD34?ve) were cultured from
a starting density of 2.5 9 105 cells/ml in RPMI1640 medium with
10 % FBS, 100 ng/ml SCF, and 20 ng/ml IL-3, and these conditions
together with 10 nM of the pan-RAR antagonist AGN194310. Cells
were cultured in 10 % FBS, 100 ng/ml SCF, 5 ng/ml IL-3, and 30 ng/
ml G-CSF to promote the optimal production of neutrophils and
monocytes. Cultures were fed with fresh medium plus agents as
required and expanded when the cell density reached 1 9 106/ml.
a Shows the cumulative number of cells and the fraction of mature
cells as measured by the FACS analysis of surface expression of
CD11b (neutrophils and monocytes). b Shows the cumulative number
of neutrophils (CD11b?ve/CD65?ve) and monocytes (CD11b?ve/
CD14?ve). Data are mean ± SEM of the values obtained from
triplicate cultures
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by cultures treated with the pan-antagonist AGN194310
was not significantly different from the kinetic observed for
cultures supplemented with 30 ng/ml G-CSF (Fig. 2a, b).
G-CSF-supplemented cultures were maintained for as long
as 55 days and also had produced fourfold more cells by
day 30. We examined the extent to which cultures differ-
entiated at similar or different rates by measuring the
appearance of CD11b?ve cells (neutrophils and monocytes)
and disappearance of CD33?ve immature myeloid cells. As
to all culture conditions, CD11b?ve-differentiated myeloid
cells appeared at a similar rate (Fig. 2a), and immature
myeloid cells declined at the same rate (data not shown).
Short-Term Expansion of CD341vehuHSC
and Progenitors Underlies Antagonist-Driven
Increased Myeloid Cell Production
The RAR antagonist AGN194310 did not slow down
myeloid cell differentiation, and therefore, we examined
whether enhanced expansion of CD34?vehuHSC and pro-
genitors might underlie the increased production of
myeloid cells and extended lifespan of cultures. In a series
of experiments, various medium conditions were compared
to optimize viability of the purified CD34?vehuHSC at the
start of experiments. We examined the use of RPMI-1640
versus various hematopoietic growth media, different sera
(FBS, horse and human), serum-free medium, SCF ± IL-3,
and culturing the cells in normal oxygen levels (20 %), and
at hypoxic conditions (1 %). Cell viability measurements
and visual inspection of cultures at early time points
revealed improved starting cell viability when CD34?ve-
huHSC cells were cultured in the hematopoietic growth
medium HPGMTM supplemented with 10 % human serum
and in normal oxygen levels. The addition of 100 ng/ml
SCF was sufficient to ensure high starting cell viability. In
all the above experiments, the levels of expansion of lin-
eage-ve/CD133?ve/CD34?vehuHSC varied five- to
eightfold by *day 30.
Figure 3a shows an *eightfold level of expansion of
lineage-ve/CD133?ve/CD34?vehuHSC at day 30 when
these cells were cultured in HPGMTM supplemented with
10 % human serum and 100 ng/ml SCF. The addition of
the pan-antagonist AGN194310, at 100 nM, led to an
increase in the rate of expansion of lineage-ve/CD133?ve/
CD34?vehuHSC and the level of expansion of these cells,
was increased to *18-fold at day 30 (mean value for seven
donors). Antagonizing RARa was sufficient to enhance
expansion of lineage-ve/CD133?ve/CD34?ve huHSC and
antagonizing RARc did not improve cell expansion
(Fig. 3a). In experiments using a further eight different
donors, we used the pan-antagonist and the a antagonist.
For all 15 donors, antagonizing either all RARs or RARa
enhanced expansion of lineage-ve/CD133?ve/CD34?ve
cells to the extent of around 20-fold, as compared to an
8–10-fold expansion seen in control cultures. Enhanced
Fig. 3 Antagonising RARa enhances ex vivo expansion of human
hematopoietic stem cells. a Purified lineage-ve/CD133?ve/CD34?ve-
cells were cultured in HPGM supplemented with 10 % human serum
and 100 ng/ml SCF and in the presence of 100 nM of either a pan or a
or c RAR antagonist. Lineage-ve/CD133?ve/CD34?vecells were
measured by the multi-color FACS analysis. The data shown are
from seven separate experiments using seven different donors. Data
are mean ± SEM. b At 2 weeks, cells harvested from cultures of
control cells (shaded bars), and cells grown in the presence of the
pan-RAR antagonist (cross-hatched bars) and absence of antagonist
(solid bars) were plated into a standard methylcellulose assay to
determine numbers of various colony-forming cells. The numbers on
the graph show the fold level of expansion of colony-forming units as
compared to control cultures. CFU colony-forming unit, CFU-GEMM
granulocyte/erythroid/megakaryocyte/macrophage colony-forming
unit, CFU-GM granulocyte/macrophage colony-forming unit, BFU-
E burst-forming unit-erythroid, CFU-E colony-forming unit-erythroid
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expansion occurred when cells from some donors were
cultured in both flasks and wells.
For CD34?vehuHSCs cultured in wells for 2 weeks in
the presence and absence of the pan-RAR antagonist
AGN194310 (at 100 nM), we examined the presence of
week-five CAFC, by plating onto MS5 feeder cells, and
whether established week-five CAFC cultures were able to
produce CFUs, to measure the presence of LTC-IC. CAFC
and LTC-IC were only present in pan-RAR-antagonized
wells (two donors). For 2 donors and at 2 weeks, we also
examined the presence of CFUs in cultures grown in the
presence and absence of the pan-antagonist AGN194310
(at 100 nM). As to culture of cells with the pan-antagonist
AGN194310 vs control cultures, CFU-GEMM were 3 % of
the total colony-forming units versus not detected, CFU-
GM were 56 vs 93 %, and BFU-E together with CFU-E
were 41 vs 7 %. The presence of the antagonist led to
increases in the total number of CFUs, CFU-GEMM, and
CFU-GM of between 10- and 30-fold. In control cultures,
BFU-E/CFU-Es were at a very low level (7 % of total
colonies) and the presence of the antagonist led to a high
value for the expansion of these CFUs of 80- to 110-fold
(Fig. 3b). This increase in BFU-E/CFU-E might be related
to antagonism of the effect of ATRA that is present in FBS,
as ATRA can specify a granulocyte fate (Tocci et al. 1996).
Despite the sustained presence of CFUs, including main-
tenance of CFU-GEMM, in antagonist-treated cultures,
these cultures gradually differentiated to produce neu-
trophils and macrophages, as shown in Fig. 2.
Selective Transactivation of RARa, RARb,
and RARc by ATRA Is Concentration Related
The RARc antagonist did not have an effect on the
expansion of lineage-ve/CD133?ve/CD34?vehuHSC
(Fig. 3), and the kinetics of the production of total cells,
neutrophils, and monocytes observed for RARc antagonist-
treated cultures were identical to those shown for the
control culture in Fig. 2. By day 20, around fourfold more
cells (largely myeloid) had been produced in the a antag-
onist-treated cultures than in the c antagonist-treated and
control cultures.
A closed helix 12 conformation in RARc, and RARb
has been reported to block binding of corepressors, and
these RARs may activate expression of target genes in the
absence of ligand (Farboud et al. 2003; Hauksdottir et al.
2003). We examined the levels of ATRA required to
agonize RARs by transfecting CV-1 and LNCaP cells with
an expression vector for each of the RAR isoforms together
with an RAR reporter construct and treating these cells
with ATRA. At concentrations below 10-9 M, preferential
transactivation of RARb and RARc was observed
(EC50’s = 0.39 9 10
-9 and 0.36 9 10-9 M, respec-
tively), with maximal activation occurring at *5 9
10-9 M ATRA. ATRA had a minimal effect on transacti-
vation via RARa at concentrations below 10-9 M
(EC50 = 12 9 10
-9 M) and a maximal effect was not
observed until the ATRA concentration approached
10-7 M (Fig. 4a). Figure 4b shows LNCaP cells
Fig. 4 ATRA stimulates





transactivation. The effect of
increasing concentrations of
ATRA on RARa-, RARb-, and
RARc-mediated transactivation
in a CV-1 cells and b serum-
free-adapted LNCaP cells. Cells
were transfected as described in
the experimental section and
were treated with 10-10 to
10-6 M ATRA for 24 h. Results
shown are from a typical
experiment performed in
triplicate and are expressed as
RLU (arbitrary units) ± SEM.
To correct for differences in
transfection efficiency between
samples values were normalized
with respect to b-galactosidase
activity
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transfected with an expression vector for RARc and
reporter plasmid that ATRA also stimulated transactivation
at sub-nanomolar concentrations (EC50 = 2.4 ± 1.0 9
10-10 M). Much higher concentrations of ATRA were
required to produce significant transactivation of RARa for
LNCaP cells transfected with this isoform (EC50 = 1.9 ?
0.4 9 10-8 M) (Fig. 4b). These findings reveal that a tis-
sue concentration of ATRA of *10-9 M and below will
selectively activate RARc, and a much higher concentra-
tion (10-9 M) is required to maximally activate RARa.
Discussion
Previous studies have shown that agonizing RARa is suf-
ficient to drive growth arrest and neutrophil differentiation
of the promyeloid cell line HL60. Similarly, the RARa
agonist was effective in driving neutrophil differentiation
of NB-4 cells, and like ATRA, it enhanced monocyte dif-
ferentiation of NB-4 and KG1 cells when used in
combination with a low dose of 1,25D. In regard to the
later, the RARa agonist was more potent than ATRA, as
was used at 100 nM vs 1 lM ATRA. These findings are in
keeping with activation of RARa which promotes myeloid
cell differentiation.
Antagonizing RARs in cultures of CD34?vehuHSCs
increased the generation of mature neutrophils and mono-
cytes and prolonged the lifespan of the culture. We did not
see a slowing down of differentiation, and the increased
myeloid cell production was due to the enhancement of the
short-term expansion of CD34?vehuHSC and progenitor
cells. Abrogating RARa activity was sufficient to enhance
expansion of CD34?vehuHSC and increase myeloid cell
production. The improved level of expansion of CD34?-
vehuHSC may not be sufficient to be of benefit to rapidly
expanding these cells in the case of an inadequate harvest
for transplantation. However, RAR antagonist-provoked
increased neutrophil production may be of benefit to
patients with neutropenia if the effect can be seen in vivo.
Early work by Purton et al. (1999) highlighted the
importance of retinoids to the differentiation of primitive
hematopoietic cells. These workers showed that ATRA
delays the differentiation of precursor cells, enhances the
terminal maturation of progenitors that are committed to
granulocyte/monocyte differentiation (Purton et al. 1999),
and enhances the long-term repopulating activity of cul-
tured HSCs (Purton et al. 2000). Walkley et al. (2002) and
Chee et al. (2013) administered the pan-antagonist
AGN194310 to mice and observed increases in myeloid
progenitor cells and mature myeloid cells. As such, find-
ings from these mouse studies and the CD34?vehuHSC
culture experiments are in agreement. An AGN194310-
provoked expansion of granulopoiesis was not seen in
knockout mice lacking the receptor for G-CSF (G-CSFR)
and Chee et al. (2013) hypothesized that G-CSFR signaling
and RARs interact to regulate myeloid cell differentiation.
In this regard, similar enhancement of myelopoiesis was
seen in cultures of CD34?vehuHSC supplemented with
either AGN194310 or G-CSF: the pan-antagonist appears
to mimic the presence of G-GSF. The antagonist-provoked
expansion of myelopoiesis may not be intrinsic to mouse
and human HSC, and Chee and co-workers (2013) have
concluded that the increase in myeloid cells in mice treated
with AGN194310 was due to an increased production of
G-CSF. This is a possibility for AGN19430-treated cultures
of CD34?vehuHSC, as macrophages appear early, increase
in number, and produce G-CSF (Chang et al. 2015;
Demetri and Griffin 1991; Hareng and Hartung 2002).
Even so, pathways that are both GSF-independent and
RAR-independent exist to ensure granulopoiesis, as neu-
trophils are produced in mice doubly null for G-CSF and
RARa or RARc (Chee et al. 2013).
It was surprising to observe that the RARc antagonist
did not significantly affect cultures of CD34?vehuHSC, as
Purton and co-workers have reported that RARc-knockout
mice have a reduced number of HSC. These workers also
investigated the repopulating capacity of lineage-vec-
kit?veSca1?ve (LSK?) cells from wild-type, RARc?/?,
RARa-/-, and RARc-/--mutant mice after culturing these
cells for 14 days with ATRA. The findings from these
experiments led to the conclusion that RARc mediates the
balance between HSC self-renewal and differentiation
(Purton et al. 2006). However, the findings from studies of
the influence of RARc on cultures of CD34?vehuHSC and
mouse LSK? cannot be compared directly for two reasons.
The absence of receptor (null mice) and use of ATRA, in
the case of the mouse LSK? experiments, is not the same
as the presence of antagonized or otherwise RARc as to the
CD34?vehuHSC experiments. In addition, mouse LSK?
cells and CD34?vehuHSC are different in the extent of their
cellular heterogeneity. In particular, CD34?vehuHSC are a
less pure population of ‘‘true’’ stem cells which may have
precluded seeing an effect on cells that are repopulating.
The role of RARc is confounded by reports that this
receptor does not repress and functions as an agonist when
ligand is absent/undetectable (Farboud et al. 2003;
Hauksdottir et al. 2003). We examined the possibility that
RARc is activated by an exceedingly low level of ATRA.
Indeed, reporter assays revealed that ATRA activates
RARc at sub-nanomolar concentrations (10-10 M): a much
higher concentration is required to activate RARa
(10-8 M). The importance of this preferential activation is
the overall tissue level of ATRA is low, as measured by
high-performance liquid chromatography-mass spectrom-
etry (Bleul et al. 2015), and RARs will be differentially
activated, as the local concentration varies. In particular,
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the levels of ATRA in embryonic tissues are tightly con-
trolled, gradients affect differential gene expression, and
correct development (Rhinn and Dolle´ 2012), and bound-
aries are controlled by the ATRA-metabolizing enzyme
retinaldehyde reductase DHRS3 (Billings et al. 2013).
In vitro, stem cell differentiation can be regulated by
controlling the ATRA gradient in a 3D scaffold (Tzezana
et al. 2012). A striking example of the influence of local
increase in the level of ATRA is that production by den-
dritic cells in the gut imprints the phenotype and gut
homing tropism of effector T cells (Iwata et al. 2004).
In this study, a pharmacological amount of ATRA
(1 lM) was used to differentiate NB-4 and KG1 cells,
which is in keeping with activation of RARa to favor
differentiation. Nanomolar ATRA should just lead to
transactivation of RARc, and the physiological importance
of selectively activating RARc has been revealed by
treating zebra fish embryos with a low amount (10 nM) of
an RARc agonist (AGN205327). Stem cell populations
were maintained at the expense of the development of
bones and neural ganglia from cranial neural crest stem
cells and pectoral and caudal fins from mesodermal stem
cells. Appropriate development was restored by agonist
washout or reversal with the RARc antagonist. Hence,
RARc remaining in its non-ligand bound state or at a low
level of activation is important to whether the above stem
cell populations make a decision to adopt a fate and/or
differentiate (Wai et al. 2015).
In summary, the findings reported here and by other
workers support the notion that the balance of expression
of RARa and RARc and activities of these receptors,
which can be governed by the local availability of ATRA,
are important to HSCs retaining this status or embarking on
myeloid cell differentiation. RARs and G-CSF appear to
cooperate in their action which is of particular interest as
growth factors, that include G-CSF, GM-CSF, M-CSF,
erythropoietin, and Flt3 ligand, can instruct cell-fate deci-
sions (reviewed in Brown et al. 2015; Grover et al. 2014;
Metcalf 1991; Metcalf and Burgess 1982; Mossadegh-
Keller et al. 2013; Rieger et al. 2009; Tsapogas et al. 2014).
An understanding of the cooperative actions of RARs and
G-CSF may well provide a better resolve to how HSCs
govern their status.
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